Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas·2022·New England Journal of Medicine
DOI 10.1056/nejmoa2202170

Cited by (1,000)

Items 301–400 of 1,000

  1. Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
    Lucy Corke, Janice J.N. Li, Natasha B. Leighl, Lawson Eng · 2022 · Current Oncology
  2. Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
    Wenjie Wu, Qian Liu, Pu-Gen An, Lin Wang, Jianyun Zhang, Yan Chen, Tong Zhang, Jie Zhang · 2023 · Frontiers in Immunology
  3. Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
    Caroline L. O’Leary, Nicole Pierce, Sandip Pravin Patel, Jarushka Naidoo · 2023 · Journal of Thoracic Oncology
  4. Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
    Yanhao Liu, Cheng Xu, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen et al. · 2022 · Frontiers in Immunology
  5. Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
    Xinyu Wu, Yi Fung Chau, Hua Bai, Xiaofei Zhuang, Jie Wang, Jianchun Duan · 2023 · Frontiers in Oncology
  6. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer
    Chiara Reina, Berina Šabanović, Chiara Lazzari, Vanesa Gregorc, Christopher Heeschen · 2024 · Translational research
  7. Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
    Claudia Parisi, Pamela Abdayem, Marco Tagliamento, Benjamin Besse, David Planchard, Jordi Remón, Gabriele Minuti, Federico Cappuzzo, Fabrice Barlési · 2024 · Cancer Treatment Reviews
  8. Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
    Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie P.L. Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo · 2025 · CA A Cancer Journal for Clinicians
  9. International expert consensus on immunotherapy for early-stage non-small cell lung cancer
    on behalf of CATO consensus group, Wenhua Liang, Kaican Cai, Qingdong Cao, Chun Chen, Haiquan Chen, Jun Chen, Ke‐Neng Chen, Qixun Chen, Tianqing Chu et al. · 2022 · Translational Lung Cancer Research
  10. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
    Trudy C. Wu, Annalise Stube, Carol Felix, Denise K. Oseguera, Tahmineh Romero, Jonathan Wade Goldman, Edward B. Garon, Jay M. Lee, John A. Glaspy, Aaron Elliott Lisberg et al. · 2023 · International Journal of Radiation Oncology*Biology*Physics
  11. Gender Differences and miRNAs Expression in Cancer: Implications on Prognosis and Susceptibility
    Santino Caserta, Sebastiano Gangemi, Giuseppe Murdaca, Alessandro Allegra · 2023 · International Journal of Molecular Sciences
  12. Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma
    Jane Yanagawa, Linh My Tran, Ramin Salehi‐Rad, Raymond J. Lim, Camelia Dumitras, Eileen Fung, William D. Wallace, Ashley Elizabeth Prosper, Gregory A. Fishbein, Conor V. Shea et al. · 2023 · Cancer Research
  13. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
    Arta Monir Monjazeb, Megan Eileen Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander D. Borowsky, Amin J. Mirhadi, Stephen Lawrence Shiao, Laurel A. Beckett et al. · 2023 · Nature Communications
  14. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges
    Jordi Remón, Stephanie P.L. Saw, Francesco Cortiula, Pawan Kumar Singh, Jessica Menis, Giannis Mountzios, Lizza E.L. Hendriks · 2023 · Journal of Thoracic Oncology
  15. Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials
    Nie, Runcong, Chen, Foping, Provencio, Mariano, Wang, Yun, van den Ende, Tom, van Laarhoven, Hanneke W.M., Yuan, Shuqiang, Pless, Miklos, Hayoz, Stefanie, Zhou, Zhiwei et al. · 2023 · European Journal of Cancer
  16. Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
    Jun Zeng, Bin Yi, Ruimin Chang, Yufan Chen, Zhongjie Yu, Yang Gao · 2023 · Frontiers in Oncology
  17. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial
    Chao Sun, Xu Wang, Yinghui Xu, Guoguang Shao, Xi Chen, Yunpeng Liu, Peng Zhang, Xingyu Lin, Xiaobo Ma, Shi Qiu et al. · 2024 · EClinicalMedicine
  18. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
    Allison E.B. Chang, Andrew J. Piper-Valillo, Raymond H. Mak, Michael D. Lanuti, Alona Muzikansky, Julia K. Rotow, Pasi Antero Janne, Mari A. Mino-Kenudson, Steven Swanson, Cameron D. Wright et al. · 2024 · The Oncologist
  19. Modeling lung adenocarcinoma metastases using patient-derived organoids
    Yuan Liu, Manendra B. Lankadasari, Joel A. Rosiene, Kofi E. Johnson, Juan Zhou, Samhita Bapat, Lai-Fong Chow-Tsang, Huasong Tian, Brooke Mastrogiacomo, Di He et al. · 2024 · Cell Reports Medicine
  20. New Immuno-oncology Targets and Resistance Mechanisms
    Molly C. Tokaz, Christina S. Baik, A. McGarry Houghton, Diane Tseng · 2022 · Current Treatment Options in Oncology
  21. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
    Bahman Abedi Kiasari, Arash Abbasi, Nadia Ghasemi Darestani, Nasim Adabi, Arsalan Moradian, Yalda Yazdani, Golsa Sadat Hosseini, Nasrin Gholami, Sheida Janati · 2022 · International Immunopharmacology
  22. Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma
    Bharathi Muthusamy, Kira Raskina, Katherine T Lofgren, Gerald Li, Khaled A. Tolba, Karen Schwed, Emily H. Castellanos, Richard S.P. Huang, Geoffrey R. Oxnard, Alexa Betzig Schrock et al. · 2022 · Journal of Thoracic Oncology
  23. Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers
    Hongsheng Deng, Hengrui Liang, Jiawei Chen, Wei Wang, Jianfu Li, Shan Xiong, Bo Cheng, Caichen Li, Zhuxing Chen, Haixuan Wang et al. · 2022 · Translational Lung Cancer Research
  24. Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
    Fenghui Zhuang, E Haoran, Jia Huang, Junqi Wu, Long Xu, Lei Zhang, Qiang Li, Chongwu Li, Yue Zhao, Minglei Yang et al. · 2023 · Lung Cancer
  25. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
    Hao Xu, Tengyun Li, Guoyi Shao, Weizhi Wang, Zhongyuan He, Jianghao Xu, Yawei Qian, Hongda Liu, Han Ge, Linjun Wang et al. · 2023 · Frontiers in Immunology
  26. A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (Cohort Study)
    Hongtao Duan, Liang Shi, Changjian Shao, Yuanyong Wang, Zhaoyang Wang, Yunfeng Ni, Jinbo Zhao, Jianyong Sun, Liping Tong, Jie Lei et al. · 2023 · International Journal of Surgery
  27. Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
    Tatiana Viktorovna Kudling, James H.A. Clubb, Santeri Artturi Pakola, Dafne C.A. Quixabeira, Iris A.K. Lähdeniemi, Camilla Heiniö, Victor Arias, Riikka Havunen, Víctor Cervera-Carrascón, João Manuel Santos et al. · 2023 · OncoImmunology
  28. Single-cell dissection of tumor microenvironmental response and resistance to cancer therapy
    Yikai Luo, Han Liang · 2023 · Trends in Genetics
  29. Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy
    Akhilesh Mishra, Kuldeep Gupta, Dhiraj Kumar, Gabriela Lofland, Ajay Sharma, Lilja B. Sólnes, Steven P. Rowe, Patrick M. Forde, Martin G. Pomper, Edward W. Gabrielson et al. · 2023 · Journal for ImmunoTherapy of Cancer
  30. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer
    Hope A. Feldman, Boris Sepesi, Cheuk Hong Leung, Heather Yan Lin, Annikka Weissferdt, Apar Pataer, William N. William, Garrett L. Walsh, David C. Rice, Jack A. Roth et al. · 2023 · Journal of Thoracic and Cardiovascular Surgery
  31. A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205
    Jo Raskin, Veerle F.M. Surmont, Alexander P.W.M. Maat, Maha Yahia, Sjaak A. Burgers, Yassin Pretzenbacher, Frédéric De Ryck, Robin Cornelissen, Houke M. Klomp, Ana Christina Araripe de Moraes Souza Oliveira et al. · 2024 · European Respiratory Journal
  32. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)
    Javier Martín‐Broto, Roberto Diaz-Beveridge, David S. Moura, Rafael F. Ramos, Javier Martínez‐Trufero, Irene Carrasco-García, Ana Sebio, Enrique González‐Billalabeitia, Antonio M. Gutierrez, Javier Fernández-Jara et al. · 2024 · Journal of Clinical Oncology
  33. The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers
    Messaoudene, Meriem, Ferreira, Stéphanie, Saint-Lu, Nathalie, Ponce, Mayra, Truntzer, Caroline, Boidot, Romain, Le Bescop, Clément, Loppinet, Thomas, Corbel, Tanguy, Féger, Céline et al. · 2024 · Nature Communications
  34. Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non–small cell lung cancer
    Arvind Kumar, Deepti H. Srinivasan, Alexandra L. Potter, Camille A. Mathey-Andrews, Michael D. Lanuti, Linda W. Martin, Chi‐Fu Jeffrey Yang · 2023 · Journal of Thoracic and Cardiovascular Surgery
  35. Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer
    Russell Seth Martins, Syed Shahzad Razi, Ahmed Alnajar, Kostantinos Poulikidis, M. Jawad Latif, Jeffrey Luo, Faiz Y. Bhora · 2024 · The Annals of Thoracic Surgery
  36. Pathological response in resectable non–small cell lung cancer: a systematic literature review and meta-analysis
    Nathalie A. Waser, Melanie Quintana, Bernd Schweikert, Jamie E. Chaft, Lindsay R. Berry, Ahmed Adam, Lien Vo, John R. Penrod, Joseph Fiore, Donald A. Berry et al. · 2024 · JNCI Cancer Spectrum
  37. A Review of Immunotherapy in Non-Small-Cell Lung Cancer
    Mariana Pilon Capella, Steph A. Pang, Marcos Aurélio Fonseca Magalhães, Khashayar Esfahani · 2024 · Current Oncology
  38. JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14/m6A/SLC3A2 axis mediated cell ferroptosis
    Huanxiang Chen, Nan Xiao, Chenxing Zhang, Yang Li, Xiangzhuan Zhao, Ruike Zhang, Lu Bai, Qiaozhen Kang, Junhu Wan, Hongyang Liu · 2025 · Journal of Translational Medicine
  39. Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer
    Yoshinori Imamura, Masafumi Kanno, Shigeharu Fujieda · 2025 · Cancer Treatment Reviews
  40. Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer
    Yuqian Wang, Cheng Jiang, Huiling Zhou, Rui Han · 2025 · Experimental Hematology and Oncology
  41. Dynamic 18F‐FDG PET / CT can predict the major pathological response to neoadjuvant immunotherapy in non‐small cell lung cancer
    Zhiyong Chen, Rui Fu, Xiaoyue Tan, Li‐Xu Yan, Wen‐Fang Tang, Zhen‐Bin Qiu, Yi‐Fan Qi, Yufa Li, Qingyi Hou, Yi-Long Lung Cancer Wu et al. · 2022 · Thoracic Cancer
  42. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
    Matthieu Roulleaux Dugage, Víctor Albarrán-Artahona, Juan Carlos Laguna, Nathalie Chaput, Stéphane Vignot, Benjamin Besse, Laura Mezquita, Édouard Auclin · 2023 · European Journal of Cancer
  43. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
    Quanying Tang, Shikang Zhao, Ning Zhou, Jinling He, Lingling Zu, Tingwen Liu, Zuoqing Song, Jun Chen, Ling Peng, Song Xu · 2023 · International Journal of Oncology
  44. Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non–small cell lung cancer
    Xiang Li, Qiuyuan Li, Fujun Yang, Erji Gao, Lei Lin, Yaqiang Li, Song Xiao, Liang Duan · 2023 · Journal of Thoracic and Cardiovascular Surgery
  45. Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients
    Daquan Wang, Bo Qiu, Qianwen Liu, Liangping Xia, Songran Liu, ChaoJie Zheng, Hui Liu, Yiwen Mo, Xu Zhang, Yingying Hu et al. · 2023 · European Journal of Nuclear Medicine and Molecular Imaging
  46. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
    Lee Jy, Richie Rashmin Bhandare, Sai H. S. Boddu, AFZAL BASHA SHAIK, Lakshmana Prabu Saktivel, Gaurav Gupta, Poonam Negi, Muna M. Barakat, Sachin Kumar Singh, Kamal Dua et al. · 2024 · Biomedicine & Pharmacotherapy
  47. Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy
    Dingpin Huang, Lin Chen, Yangyang Jiang, Enhui Xin, Fangyi Xu, Yi Gan, Rui Xu, Fang Wang, Haiping Zhang, Kaihua Lou et al. · 2024 · Frontiers in Oncology
  48. Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease
    Elad Sandbank, Anabel Eckerling, Adam Margalit, Liat Sorski, Shamgar Ben‐Eliyahu · 2023 · Current Oncology
  49. The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancer
    Yi‐Ru Bai, Wei‐Guang Yang, Rui Jia, Ju‐Shan Sun, Dandan Shen, Hong‐Min Liu, Shuo Yuan · 2024 · Medicinal Research Reviews
  50. LTBR acts as a novel immune checkpoint of tumor‐associated macrophages for cancer immunotherapy
    Liang Wang, Jieyi Fan, Sifan Wu, Shilin Cheng, Junlong Zhao, Fan Fan, Chun-Chen Gao, Rong Qiao, Qiqi Sheng, Yiyang Hu et al. · 2024 · iMeta
  51. Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
    K. Sugiyama, Anderley Gordon, Sanjay Popat, Alicia F. C. Okines, James Larkin, Ian Chau · 2025 · ESMO Open
  52. Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
    Kentaro Tanaka, Jun Sugisaka, Yoshimasa Shiraishi, Yasutaka Watanabe, Haruko Daga, Koichi Azuma, Kazumi Nishino, Masahide Mori, Takayo Ota, Haruhiro Saito et al. · 2025 · Nature Communications
  53. Safety and Feasibility of Pulsed Electric Field Ablation for Early‐Stage Non‐Small Cell Lung Cancer Prior to Surgical Resection
    Marcelo Fernando Jiménez, Javier Flandes, Erik H.F.M. van der Heijden, Calvin S.H. Ng, Jeffrey S. Iding, José Fernández García-Hierro, Borja Recalde Zamacona, Roel L.J. Verhoeven, Rainbow W. H. Lau, Alicia Moreno‐Gonzalez et al. · 2025 · Journal of Surgical Oncology
  54. Lung cancer recurrence after neoadjuvant immunotherapy
    Hao Li, Fatemehsadat Pezeshkian, Yue Xie, Emanuele Mazzola, Rafael Ribeiro Barcelos, Fatemeh Hooshmand, Tianxiao Han, Sanna Laaksonen, Lynette Marie Sholl, Carla Vega et al. · 2025 · Journal of Thoracic and Cardiovascular Surgery
  55. Immunotherapy for resectable lung cancer
    Colum Dennehy, Michael R. Conroy, Patrick M. Forde · 2025 · Cancer
  56. Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
    Joshua E. Reuss, Paul K. Lee, Reza John Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Öner et al. · 2025 · Nature Medicine
  57. Clinical development of cancer vaccines
    John B.A.G. Haanen, Ton N. Schumacher, Jonathan C. Kagan, Edward F. Fritsch, Catherine J. Wu · 2026 · Nature Medicine
  58. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review
    Collin Michael Blakely, Walter Weder, Lukas Bubendorf, Jianxing He, Margarita Majem, Yu Shyr, Jamie E. Chaft · 2023 · Lung Cancer
  59. Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Mei Zhao, Shanwen Chen, Conggui Li, Yingying Du, Ping Li · 2023 · Cancers
  60. Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
    Michele Montrone, Gerardo Rosati, Vito Longo, Annamaria Catino, Raffaella Massafra, Annalisa Nardone, Francesco Pesola, Elisabetta Sara Montagna, Ilaria Marech, Pamela Pizzutilo et al. · 2023 · Journal of Clinical Medicine
  61. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma
    Honglei Wang, Zeying Jiang, Qihua Wang, Tong Wu, Fangzhou Guo, Zhengyuan Xu, Weixiong Yang, Shicong Yang, Shi‐Ting Feng, Xiaoyan Wang et al. · 2023 · European Journal of Cancer
  62. Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
    Lanyi Nora Chen, Alexander Z. Wei, Catherine A. Shu · 2023 · Therapeutic Advances in Medical Oncology
  63. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non–Small-Cell Lung Cancer
    Milena Petranović, Shaunagh McDermott, Sarah Mercaldo, Brent P. Little, Alexander Graur, Kevin B. Huang, Florian Johannes Fintelmann, Subba Rao Digumarthy, Justin F. Gainor · 2023 · Clinical Lung Cancer
  64. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study
    Ying Liu, Lei Xiong, Yue Chen, Ruoxue Cai, Xinyu Xu, Tian Wang, Yiyu Guo, Luxi Ruan, Ying Fang, Quanan Zhang et al. · 2023 · Human Vaccines & Immunotherapeutics
  65. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study
    Oliver John Kennedy, Nadia Hage Ali, Rebecca J. Lee, Phillip J. Monaghan, Safwaan Adam, Tim Cooksley, Paul C. Lorigan · 2024 · European Journal of Cancer
  66. Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study
    Leilei Wu, Bo Cheng, Xiaojiang Sun, Zhenshan Zhang, Jingjing Kang, Yun Chen, Qinghua Xu, Shuangyan Yang, Yujie Yan, Shengxiang Ren et al. · 2024 · MedComm
  67. Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
    Milou M. F. Schuurbiers, Christopher G. Smith, Koen Johan Hartemink, Robert Campbell Rintoul, Davina Gillian Gale, Kim Monkhorst, Bas L R Mandos, Anna Paterson, Daan A. van den Broek, Nitzan Rosenfeld et al. · 2025 · PLoS Medicine
  68. A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma
    William Zhao, Thinh T. Nguyen, Atharva Bhagwat, Akhil Kumar, Bruno Giotti, Benjamin Kepecs, Jason L. Weirather, Navin R. Mahadevan, Åsa Segerstolpe, Komal Dolasia et al. · 2025 · Nature Cancer
  69. Neoadjuvant Prehabilitation Therapy for Locally Advanced Non–Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care
    Severin Schmid, Enrico Maria Minnella, Yohann Pilon, Merav Rokah, Roni F. Rayes, Sara Najmeh, Jonathan Cools‐Lartigue, Lorenzo Edwin Ferri, David S. Mulder, Christian Sirois et al. · 2022 · Clinical Lung Cancer
  70. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non–Small Cell Lung Cancer
    Girish S. Shroff, Chad D. Strange, Jitesh Ahuja, Mehmet Altan, Ajay Sheshadri, Ebru Ünlü, Mylene T. Truong, Ioannis Vlahos · 2022 · Radiographics
  71. Physicochemical properties of green synthesised ZnO nanoparticles and utilisation for treatment of breast cancer
    Raunak Saha, Karthik Subramani, Sreenath Dey, Saheri Sikdar, Aran Incharoensakdi · 2023 · Process Biochemistry
  72. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
    Biagio Ricciuti, Arielle Elkrief, Joao V. Alessi, Xinan Wang, Yvonne Y. Li, Hersh V. Gupta, Daniel M. Muldoon, Arrien A. Bertram, Federica Pecci, Giuseppe Lamberti et al. · 2023 · Clinical Cancer Research
  73. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
    Xiao Hu, Jin Ren, Qianfei Xue, Rumei Luan, Dongyan Ding, Jie Tan, Xin Su, Junling Yang · 2023 · International Journal of Oncology
  74. Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis
    Riona Aburaki, Yu Fujiwara, Kohei Chida, Nobuyuki Horita, Misako Nagasaka · 2024 · Cancer Treatment Reviews
  75. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
    Heng Jiao, Siyun Lin, Jianmin Gu, Dongxian Jiang, Peng Cui, Zhiliang Huang, Yong Fang, Hao Wang, Lin Miao, Han Tang et al. · 2025 · Molecular Cancer
  76. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
    Julie S Deutsch, Richard A. Scolyer, Elizabeth M. Burton, Klaus Johannes BUSAM, K.Y. Chen, Ashley Cimino‐Mathews, Tricia R. Cottrell, Carlos E. de Andrea, Pierre Fiset, Georgina Venetia Long et al. · 2025 · Annals of Oncology
  77. Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment
    Ignace B. Vergote, Teresa Mercade Macarulla, Fred R. Hirsch, Carsten Hagemann, David Scott Miller · 2023 · Cancers
  78. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment
    Nikhil Yegya‐Raman, Eva E. Berlin, Steven Joel Feigenberg, Bonnie Ky, Lova Sun · 2023 · Current Oncology Reports
  79. PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells
    Zhenzhen Hui, Yulin Ren, Dong Zhang, Yulong Chen, Wenwen Yu, Jie Cao, Liang Liu, Tao Wang, Shanshan Xiao, Liuqing Zheng et al. · 2023 · npj Precision Oncology
  80. Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
    Luyao Wang, Zongxing Yang, Fucheng Guo, Yurong Chen, Jiarui Wei, Xiangpeng Dai, Xiaoling Zhang · 2023 · Frontiers in Immunology
  81. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre
    Erica C. Koch Hein, Maysa Vilbert, Ian Hirsch, Maurício Fernando Silva Almeida Ribeiro, Thiago Pimentel Muniz, Cynthia Fournier, Khaled Abdulalem, Erick Figueiredo Saldanha, Erika A. Martinez, Anna Spreafico et al. · 2023 · Cancers
  82. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
    Roger Li, Luigi Nocera, Kyle M. Rose, Daniele Raggi, Shreyas U. Naidu, Chiara Mercinelli, Antonio Cigliola, Valentina Tateo, Damiano Alfio Patanè, George Daniel Grass et al. · 2024 · European Urology Oncology
  83. Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma
    Alisa B. Ageenko, Natalia S. Vasileva, Vladimir Alexandrovich Richter, Elena Vladimirovna Kuligina · 2024 · International Journal of Molecular Sciences
  84. New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors
    Stephanie P.L. Saw, Xiuning Le, Lizza E.L. Hendriks, Jordi Remón · 2024 · American Society of Clinical Oncology Educational Book
  85. Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
    Yu Fujiwara, Shumei Kato, Razelle Kurzrock · 2026 · Hematology/Oncology Clinics of North America
  86. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer
    Daniel Johnathan Hughes, Eleni Josephides, Robert O’Shea, Thubeena Manickavasagar, Carolyn Horst, Sarah J. Hunter, Philippe Tanière, Daisuke Nonaka, Mieke Van Hemelrijck, James F. Spicer et al. · 2024 · European Radiology
  87. Cancer therapy–related salivary dysfunction
    Cristina Paz, Annemarie Glassey, Abigail Frick, Sarah Sattar, Nicholas George Zaorsky, Grace C. Blitzer, Randall J. Kimple · 2024 · Journal of Clinical Investigation
  88. Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study
    Dan Han, Hao Li, Xin Zheng, Shenbo Fu, Ran Wei, Qian Zhao, Chengxin Liu, Zhongtang Wang, Wei Chun Huang, Shaoyu Hao · 2024 · Frontiers in Immunology
  89. Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer
    Tancredi Didier Bazan Russo, Francesco Pepe, Valerio Gristina, Andrea Gottardo, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Giulia Busuito, Lorena Incorvaia, Juliette Aimee Guerry et al. · 2025 · Future Oncology
  90. Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non–small cell lung cancer: Results from a randomized trial
    Benjamin Lee, Nathan Mynard, Abu Nasar, Jonathan Villena‐Vargas, Oliver S. Chow, Sebron W. Harrison, Brendon Matthew Stiles, Jeffrey L. Port, Nasser Khaled Altorki · 2022 · Journal of Thoracic and Cardiovascular Surgery
  91. Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer
    Arnaud Scherpereel, Etienne Martin, Laurent Brouchet, R. Corre, M. Duruisseaux, Pierre‐Emmanuel Falcoz, Philippe Giraud, Cecile Le Pechoux, Marie Wislez, Marco Alifano · 2023 · Lung Cancer
  92. Tumor Immune Microenvironment Predicts the Pathologic Response Of Neoadjuvant Chemoimmunotherapy In Locally Advanced And Oligometastatic Non–Small Cell Lung Cancer
    Rui Fa Han, Yimin Zhang, Tianhu Wang, Hualiang Xiao, Zhilin Luo, Cheng Shen, Jianghua Li, Chenglong Zhao, Li Li, Mengxiao Zhu et al. · 2022 · Cancer Science
  93. Radiotherapy and Immunotherapy in Lung Cancer
    Kristin Hsieh, Daniel R. Dickstein, Juliana Runnels, Eric J. Lehrer, Kenneth E. Rosenzweig, Fred R. Hirsch, Robert M. Samstein · 2023 · Biomedicines
  94. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
    B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica Marie Konen, Frank R. Rojas Alvarez, Luisa Maren Solis et al. · 2023 · Frontiers in Immunology
  95. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
    Yanhong Shi, Xiao-Yan Ma, Dan He, Bingwei Dong, Tianyun Qiao · 2023 · Frontiers in Immunology
  96. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non–small cell lung cancer: Evidence for surgery in advanced disease
    Nathaniel Deboever, Kyle Gregory Mitchell, Ahsan Saleem Farooqi, Ethan Bernard Ludmir, Wayne Lewis Hofstetter, Reza John Mehran, Ravi Rajaram, David C. Rice, Boris Sepesi, Stephen G. Swisher et al. · 2023 · Journal of Thoracic and Cardiovascular Surgery
  97. Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
    Guillermo Suay, Juan Carlos García‐Cañaveras, Francisco Aparisi, Agustín Lahoz, Óscar Juan · 2023 · Cancers
  98. Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC
    Eftychia Kiousi, Vasiliki Lyraraki, Georgia Lamprini Mardiki, Nikolina Stachika, Aikaterini Konstantina Damianou, Christina Panagiotis Malainou, Nikolaos Konstantinos Syrigos, Georgia Gomatou, Elias Alexandros Kotteas · 2023 · Cancers
  99. Biomarkers and experimental models for cancer immunology investigation
    Hengyi Xu, Ziqi Jia, Fengshuo Liu, Jiayi Li, Yansong Huang, Yiwen Jiang, Pengming Pu, Tongxuan Shang, Pengrui Tang, Yongxin Zhou et al. · 2023 · MedComm
  100. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer
    Cindy Y. Jiang, Lili Zhao, Michael D. Green, Shashidhar Ravishankar, Andrea M. H. Towlerton, Anthony J. Scott, Malini Raghavan, Matthew F. Cusick, Edus Houston Warren, Nithya Ramnath · 2024 · Scientific Reports